Stock Upgrades: Exact Sciences Shows Rising Relative Strength

Exact Sciences (EXAS) had its Relative Strength (RS) Rating upgraded from 66 to 71 Wednesday — a welcome improvement, but still below the 80 or better score you prefer to see.


As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.

This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock’s price action over the trailing 52 weeks matched up against all other stocks.

Decades of market research shows that the best-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if Exact Sciences can continue to show renewed price strength and hit that benchmark.

Looking For The Best Stocks To Buy And Watch? Start Here

Exact Sciences is trying to complete a consolidation with a 159.64 buy point. See if it can break out in volume at least 40% higher than normal.

The company posted -616% EPS growth in its most recent report, while sales growth came in at 58%. Keep an eye out for the company’s next round of numbers on or around May 6.

Exact Sciences earns the No. 154 rank among its peers in the Medical-Biomed/Biotech industry group. Ligand Pharmaceuticals (LGND) and Cara Therapeutics (CARA) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Evaluate Any Stock With Stock Ratings, IBD Charts And Stock Checkup

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button